Highnoon Laboratories Ltd
Public listed pharmaceutical manufacturer · Lahore · Pakistan
Publicly listed Lahore pharmaceutical manufacturer with a broad therapeutic portfolio, research and development operations and national distribution.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Highnoon Laboratories Limited
- Company type
- Public listed pharmaceutical manufacturer
- Address
- 17.5 KM, Multan Road, Lahore 53700, Pakistan · 53700
- Website
- highnoon-labs.com ↗
- Phone
- +92 42 111 000 465
- info@highnoon.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Hi-Zync DRY powder (lpSource observed | Zinc (elemental) | 100 mg + 3.64 mg | Suspension | 60 ML | 071577Official source ↗ | No indexed price | — | — |
| Hifarin | Warfarin | 5 mg | Tablet | 30 | 027983 | PKR 295.66 | PKR 9.86/tablet | 22% below median |
| Hitase | Letrozole | 2.5 mg | Tablet | 30 | 088737 | PKR 14,094.71 | PKR 469.82/tablet | 17% above median |
| Hitase | Letrozole | 2.5 mg | Tablet | 10 | 088737 | PKR 4,698.24 | PKR 469.82/tablet | 17% above median |
| Hitecxin ACT | Dihydroartemisinin + Piperaquine | 40 mg + 320 mg | Tablet | 8 | 044767 | PKR 749.01 | PKR 93.63/tablet | 11% above median |
| Hitrazole | Itraconazole | 100 mg | Tablet | 4 | 032071 | PKR 498.41 | PKR 124.60/tablet | No comparator |
| Ipratec | Ipratropium bromide | 18 mcg | Inhalation capsule | 30 | 044596 | PKR 254.14 | PKR 8.47/capsule | No comparator |
| Ipratec | Ipratropium bromide | 0.025 % | Solution | 5's x2ml Respule | 124682 | PKR 619.60 | — | No comparator |
| Lexopine | Carbamazepine | 200 mg | Tablet | 50 | 019746 | PKR 290.55 | PKR 5.81/tablet | 46% below median |
| Lexopine | Carbamazepine | 100 mg | Syrup | 120 | 024233 | PKR 92.04 | — | No comparator |
| Loprin | Acetylsalicylic acid (Aspirin) | 150 mg | Tablet | 30 | 013127 | PKR 115.64 | PKR 3.85/tablet | 58% above median |
| Loprin | Acetylsalicylic acid (Aspirin) | 300 mg | Tablet | 30 | 013128 | PKR 149.91 | PKR 5.00/tablet | 50% above median |
| Loprin | Acetylsalicylic acid (Aspirin) | 75 mg | Tablet | 100 | 014900 | PKR 280.73 | PKR 2.81/tablet | 46% above median |
| Loprin | Acetylsalicylic acid (Aspirin) | 75 mg | Tablet | 30 | 014900 | PKR 87.73 | PKR 2.92/tablet | 52% above median |
| Loprin | Acetylsalicylic acid (Aspirin) | 75 mg | Tablet | 50 | 014900 | PKR 143.28 | PKR 2.87/tablet | 49% above median |
| Loprin | Acetylsalicylic acid (Aspirin) | 75 mg | Tablet | 60 | 014900 | PKR 171.94 | PKR 2.87/tablet | 49% above median |
| Mectin | Ivermectin | 3 mg | Tablet | 6 | 059774 | PKR 191.39 | PKR 31.90/tablet | Near median |
| Mectin | Ivermectin | 3 mg | Tablet | 20 | 059774 | PKR 637.97 | PKR 31.90/tablet | Near median |
| Misar-AM | Telmisartan + Amlodipine | 40 mg + 5 mg | Tablet | 20 | 067815 | PKR 983.09 | PKR 49.15/tablet | Near median |
| Misar-AM | Telmisartan + Amlodipine | 40 mg + 5 mg | Tablet | 14 | 067815 | PKR 745.96 | PKR 53.28/tablet | Near median |
| Misar-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 20 | 069151 | PKR 1,635.63 | PKR 81.78/tablet | 20% above median |
| Misar-AM | Telmisartan + Amlodipine | 80 mg + 10 mg | Tablet | 10 | 069151 | PKR 886.50 | PKR 88.65/tablet | Near median |
| Misar-AM | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 20 | 080482 | PKR 1,082.83 | PKR 54.14/tablet | Near median |
| Misar-AM | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 14 | 080482 | PKR 821.64 | PKR 58.69/tablet | 9% above median |
| Misar-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 20 | 080483 | PKR 1,510.26 | PKR 75.51/tablet | 11% above median |
| Misar-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 14 | 080483 | PKR 1,145.97 | PKR 81.86/tablet | 20% above median |
| Misar-AM 80/10 | Telmisartan + Amlodipine | 80 mg + 10 mg | Tablet | 10 | 069151 | PKR 886.50 | PKR 88.65/tablet | Near median |
| Misar-h | Telmisartan + Hydrochlorothiazide | 80 mg + 25 mg | Tablet | 14 | 065684 | PKR 1,200.88 | PKR 85.78/tablet | Near median |
| Misar-H | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 20 | 065685 | PKR 1,666.99 | PKR 83.35/tablet | Near median |
| Misar-H | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 14 | 065685 | PKR 1,264.89 | PKR 90.35/tablet | 11% above median |
| Misar-H | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 20 | 065688 | PKR 883.34 | PKR 44.17/tablet | Near median |
| Misar-H | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 14 | 065688 | PKR 670.28 | PKR 47.88/tablet | 10% above median |
| MTX | Methotrexate | 50 mg | Injection | 1 | 016172 | PKR 886.48 | — | No comparator |
| MTX | Methotrexate | 2.5 mg | Tablet | 100 | 016173 | PKR 2,336.65 | PKR 23.37/tablet | 25% below median |
| Novirin | Ribavirin | 600 mg | Tablet | 10 | 033638 | PKR 1,477.61 | PKR 147.76/tablet | 505% above median |
| Novirin | Ribavirin | 100 mg | Capsule | 10 | 034072 | PKR 279.11 | PKR 27.91/capsule | Near median |
| Novirin | Ribavirin | 200 mg | Capsule | 10 | 034073 | PKR 466.61 | PKR 46.66/capsule | Near median |
| Novirin | Ribavirin | 400 mg | Capsule | 10 | 034074 | PKR 641.59 | PKR 64.16/capsule | 12% above median |
| Nystatin Oral | Nystatin | 100000 IU/mL | Oral drops | 30 ml | 025617 | PKR 65.18 | PKR 2.17/mL | 32% below median |
| Opinil | Naltrexone | 50 mg | Tablet | 10 | 038404 | PKR 1,132.17 | PKR 113.22/tablet | 8% below median |
| Oxaquin | Moxifloxacin | 400 mg | Tablet | 5 | 043660 | PKR 1,192.62 | PKR 238.52/tablet | 29% above median |
| Paratol | Paracetamol | 500 mg | Tablet | 200 | 004282 | PKR 573.38 | PKR 2.87/tablet | 21% below median |
| ParatolSource observed | Paracetamol | 120 mg | Held for normalizationSource reported: Tablet · structural field conflict | 60 ml | 004998Official source ↗ | No indexed price | — | — |
| Pidogrel | Clopidogrel | 75 mg | Tablet | 10 | 032074 | PKR 293.14 | PKR 29.31/tablet | 8% above median |
| Pospenem | Meropenem | 500 mg | Powder for injection | 1 | 084176 | PKR 2,009.20 | — | No comparator |
| Prepenem | Imipenem + Cilastatin | 500 mg + 500 mg | Injection | 1 | 039834 | PKR 1,846.42 | — | No comparator |
| Rivaro | Rivaroxaban | 15 mg | Tablet | 14 | 085872 | PKR 9,871.52 | PKR 705.11/tablet | Near median |
| Rivaro | Rivaroxaban | 15 mg | Tablet | 10 | 085872 | PKR 7,051.08 | PKR 705.11/tablet | Near median |
| Rivaro | Rivaroxaban | 20 mg | Tablet | 14 | 085873 | PKR 12,496.18 | PKR 892.58/tablet | Near median |
| Rivaro | Rivaroxaban | 20 mg | Tablet | 10 | 085873 | PKR 8,925.84 | PKR 892.58/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.